Showing 1801-1810 of 2216 results for "".
- Exosome Update: ELEVAI Labs Announces Pricing of $6,000,000 IPOhttps://modernaesthetics.com/news/exosome-update-elevai-labs-announces-pricing-of-6000000-ipo/2473530/Elevai Labs, Inc. announced the pricing of its initial public offering. The Offering consists of 1,500,000 shares of common stock at a public offering price of $4.00 per share, for total gross proceeds of $6,000,000 before deducting underwriting discounts and o
- AestheticsWire Exclusive: Embracing Diversity in Aestheticshttps://modernaesthetics.com/news/embracing-diversity-in-aesthetics/2473528/There’s no such thing as a one-size-fits-all approach to rejuvenation as people across genders, ethnicities, and age groups often have different concerns and aesthetic goals. This is the main takeaway from a new study that sought to better understand facial and body aesthetic conc
- Modern Aesthetics® Named Exclusive Media Partner for Octane’s Aesthetics Tech Forum for Second Year in a Rowhttps://modernaesthetics.com/news/modern-aesthetics-named-exclusive-media-partner-for-octanes-aesthetics-tech-forum-for-second-year-in-a-row/2473520/Modern Aesthetics® magazine is the exclusive media partner for Octane’s Aesthetics Tech Forum for the second consecutive year. This year’s Forum will take place at the Balboa Bay Resort in Newport Beach, Calif. January 25-26, 2024.
- Dr. Sherard A. Tatum Named New AAFPRS Presidenthttps://modernaesthetics.com/news/dr-sherard-a-tatum-named-new-aafprs-president/2473514/New York-based facial plastic and reconstructive surgeon Sherard A. Tatum, MD, is the new President of the
- Allergan Reports Positive Phase 3 Data for New Short-acting Neurotoxinhttps://modernaesthetics.com/news/allergans-trenibotulinumtoxine-bonte-smoothes-glabellar-lines-quickly/2473513/Allergan Aesthetics’ trenibotulinumtoxinE (BoNT/E) performed well for the treatment of moderate to severe glabellar lines, according to topline results from two pivotal Phase 3 studies. BoNT/E is a novel botulinum neurotoxin serotype E with a quick onset of action
- New Deadline: Allergan Aesthetics, University Lab Partners Launch Golden Passport Pitch Competition to Accelerate Aesthetics Start-Upshttps://modernaesthetics.com/news/news-you-can-use-allergan-aesthetics-university-lab-partners-launch-golden-passport-pitch-competition-to-accelerate-aesthetics-start-ups-1/2473512/University Lab Partners (ULP) and Allergan Aesthetics are launching the Golden Passport pitch competition for aesthetic startups. The Golden Passport provides the winner with a lab bench for one year and opportunities to engage with industry mentors including scientific and business lea
- Sentient Adds to C-Suitehttps://modernaesthetics.com/news/sentient-adds-to-c-suite/2473510/Brian Kirk is Sentient’s new Chief Marketing Officer (CMO), and Jennifer Redmond joins as Chief Revenue Officer (CRO). Mr. Kirk is charged with elevating Sentient's marketing investment to support Tixel by Sentient and Sentient Sculpt, wh
- Allergan Aesthetics, University Lab Partners Announce the Golden Passport Pitch Competition to Accelerate Aesthetics Start-Upshttps://modernaesthetics.com/news/allergan-aesthetics-university-lab-partners-announce-the-golden-passport-pitch-competition-to-accelerate-aesthetics-start-ups/2473509/University Lab Partners (ULP) is announcing the Golden Passport pitch competition for aesthetic startups sponsored by Allergan Aesthetics, an AbbVie Company. The Golden Passport provides the winner with a lab bench for one year and opportunities to engage with industry mentors including
- AirSculpt Technologies Teams Up NYSYNC Member Joey Fatonehttps://modernaesthetics.com/news/airsculpt-technologies-teams-up-nysync-member-joey-fatone/2473508/AirSculpt Technologies, Inc. is partnering with singer, dancer, actor Joey Fatone to share his AirSculpt experience. AirSculpt is a liposuction procedure that removes fat and tightens skin. It’s offered exclusively at Elite Body Sculpture centers.
- RelabotulinumtoxinA Update from Galdermahttps://modernaesthetics.com/news/relabotulinumtoxina-update-from-galderma/2473504/The U.S. Food and Drug Administration (FDA) has issued a Complete Response Letter (CRL) to Galderma related to its pending Biologics License Application (BLA) for RelabotulinumtoxinA for the treatment of moderate-to-severe glabellar lines associated with corrugator and/or procerus muscle activity